Ourotech is working to take the guesswork out of cancer treatment.

1. Ourotech
Cancer treatment with certainty

2. Here’s how breast cancer is being fought today

3. 1st line treatment
Herceptin combination
2nd line treatment
T-DM1
3rd line treatment
Xeloda
4th line treatment
Hormone therapy
Example: HER2+ Breast Cancer

4. Drug Resistance:
Every cancer has a different weakness

5. The Problem
Multiple drugs target the same cancer subtype
but they don’t work on all patients
Tumors can be resistant due to:
- Genetic resistance/mutation
- Tumor microenvironment
- Interaction with other cancer cells
- Interaction with healthy cells

6. Take the guess work out of cancer treatment

7. The Solution
Obtain patient tumor sample from biopsy
Grow tumors in 96 well plate using proprietary hydrogel
Test the effectiveness of drugs and combination treatments
Calculate necessary human dosage from test results
Treat the patient

8. Obtain patient
tumor sample from
biopsy
Grow tumors in 96 well
plate using proprietary
hydrogel
Test the effectiveness
of drugs and
combination treatments
Calculate necessary
human dosage from
test results
Treat the
patient

9. Proof of Concept: IC50
Drug Tested: Doxorubicin
Human IC50: 702nM Ourotech IC50: 600~650nM Alginate IC50: 200nM
IC50: industry standard measure of drug resistance
Ourotech can predict this better than the competition

10. Core Technology
Genesis
Hydrogel that mimics conditions inside
patients’ bodies for Stage 3 and 4
breast, colon, and brain cancers
Allows doctors to culture patient tumors
outside the body, create 3D tumor
models and test drug resistance on
patient derived tumors

11. $500/patient
1 order of hydrogel allows doctors to
perform in vitro testing for 1 patient.
Hydrogel is a consumable.

12. Market
TAM
SAM
SOM
14.1M New
Cancer
Diagnoses/Year
Worldwide
$7.05B Market 3.3M New Breast,
Colorectal, Brain
Cancer
Diagnoses/Year
Worldwide
$1.65B Market
407K New
Breast,
Colorectal, Brain
Cancer
Diagnoses/Year
in the US
$204M Market

13. Team
Duleeka Ranatunga, CEO Prof Jonathan Blay Prof Shirley Tang William Lin, Head of
R&D
Christina Ryu, Business
Development
Ali Nikdel, R&DMichael Kim, Head of Finance

14. Funding Roadmap
Strategic partnership
with hospitals for
preclinical trials
Strategic
partnership with big
pharma client for
clinical trials and
distribution
Start generating
revenue by
pharmaceutical drug
testing services
Optimize product
based on drug testing
and preclinical results
Seed Series A

15. Funding and Milestones
Ask: $1.5M Runway: 18 months
Milestones
Finish preclinical trials
IRB and begin FDA
510K clearance process
Generate revenues
from pharma clients
Develop new
prototypes and IP

16. Traction
2 patents pending 2 academic pilots 2 pharma pilots, sales
to start May 2017
1 Pre Clinical Trial In
Progress
Partnership for
marketing

17. 2 Year Product Development Roadmap
Develop more
humanized
hydrogels
Integrate
hydrogels with
microfluidics
and bioreactors
Use big data for
better drug
dosage
prediction
Train machine
learning
algorithms to
predict drug
resistance
Test immuno-
therapies